Monitoring adenoviral p53 transduction efficiency by yeast functional assay

M. Tada, S. Sakuma, R. D. Iggo, H. Saya, Y. Sawamura, Toshiyoshi Fujiwara, J. A. Roth

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Monitoring the transduction efficiency is of paramount importance in gene therapy. To monitor adenovirus-mediated wild-type p53 gene transfer, we have used a quantitative assay which tests the ability of human p53 to activate transcription in yeast. Selective amplification of cellular and viral p53 transcripts followed by quantitative assessment of mutant p53 content with the assay permits measurement of the wild-type p53 transduction efficiency into SF-188, U251MG and HUG31 glioblastoma cells. One reverse transcription primer tracks the wild-type/mutant ratio of endogenous p53 mRNA (P2), and the other the wild-type/mutant ratio of both endogenous and exogenous p53 mRNA (P1). Following infection of cell lines homozygous for mutant p53, the apparent transduction efficiency calculated (τ(o) = [P1 - P2]/[1 + P2]) correlated with the level of p21 expression. Transduction efficiency in heterozygous wild-type/mutant HUG31 cells increased linearly with multiplicity of infection (MOI) for τ(o) value, in keeping with theoretical predictions. These results suggest that the yeast p53 functional assay may be a useful tool for monitoring p53 gene therapy.

Original languageEnglish
Pages (from-to)339-344
Number of pages6
JournalGene Therapy
Volume5
Issue number3
Publication statusPublished - 1998

Fingerprint

p53 Genes
Genetic Therapy
Yeasts
Messenger RNA
Glioblastoma
Infection
Adenoviridae
Reverse Transcription
Cell Line

Keywords

  • Adenovirus
  • p53
  • Transcripts
  • Transduction efficiency
  • Yeast p53 functional assay

ASJC Scopus subject areas

  • Genetics

Cite this

Tada, M., Sakuma, S., Iggo, R. D., Saya, H., Sawamura, Y., Fujiwara, T., & Roth, J. A. (1998). Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Therapy, 5(3), 339-344.

Monitoring adenoviral p53 transduction efficiency by yeast functional assay. / Tada, M.; Sakuma, S.; Iggo, R. D.; Saya, H.; Sawamura, Y.; Fujiwara, Toshiyoshi; Roth, J. A.

In: Gene Therapy, Vol. 5, No. 3, 1998, p. 339-344.

Research output: Contribution to journalArticle

Tada, M, Sakuma, S, Iggo, RD, Saya, H, Sawamura, Y, Fujiwara, T & Roth, JA 1998, 'Monitoring adenoviral p53 transduction efficiency by yeast functional assay', Gene Therapy, vol. 5, no. 3, pp. 339-344.
Tada M, Sakuma S, Iggo RD, Saya H, Sawamura Y, Fujiwara T et al. Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Therapy. 1998;5(3):339-344.
Tada, M. ; Sakuma, S. ; Iggo, R. D. ; Saya, H. ; Sawamura, Y. ; Fujiwara, Toshiyoshi ; Roth, J. A. / Monitoring adenoviral p53 transduction efficiency by yeast functional assay. In: Gene Therapy. 1998 ; Vol. 5, No. 3. pp. 339-344.
@article{48323a136b194e1aa55165a54bbfe3a2,
title = "Monitoring adenoviral p53 transduction efficiency by yeast functional assay",
abstract = "Monitoring the transduction efficiency is of paramount importance in gene therapy. To monitor adenovirus-mediated wild-type p53 gene transfer, we have used a quantitative assay which tests the ability of human p53 to activate transcription in yeast. Selective amplification of cellular and viral p53 transcripts followed by quantitative assessment of mutant p53 content with the assay permits measurement of the wild-type p53 transduction efficiency into SF-188, U251MG and HUG31 glioblastoma cells. One reverse transcription primer tracks the wild-type/mutant ratio of endogenous p53 mRNA (P2), and the other the wild-type/mutant ratio of both endogenous and exogenous p53 mRNA (P1). Following infection of cell lines homozygous for mutant p53, the apparent transduction efficiency calculated (τ(o) = [P1 - P2]/[1 + P2]) correlated with the level of p21 expression. Transduction efficiency in heterozygous wild-type/mutant HUG31 cells increased linearly with multiplicity of infection (MOI) for τ(o) value, in keeping with theoretical predictions. These results suggest that the yeast p53 functional assay may be a useful tool for monitoring p53 gene therapy.",
keywords = "Adenovirus, p53, Transcripts, Transduction efficiency, Yeast p53 functional assay",
author = "M. Tada and S. Sakuma and Iggo, {R. D.} and H. Saya and Y. Sawamura and Toshiyoshi Fujiwara and Roth, {J. A.}",
year = "1998",
language = "English",
volume = "5",
pages = "339--344",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Monitoring adenoviral p53 transduction efficiency by yeast functional assay

AU - Tada, M.

AU - Sakuma, S.

AU - Iggo, R. D.

AU - Saya, H.

AU - Sawamura, Y.

AU - Fujiwara, Toshiyoshi

AU - Roth, J. A.

PY - 1998

Y1 - 1998

N2 - Monitoring the transduction efficiency is of paramount importance in gene therapy. To monitor adenovirus-mediated wild-type p53 gene transfer, we have used a quantitative assay which tests the ability of human p53 to activate transcription in yeast. Selective amplification of cellular and viral p53 transcripts followed by quantitative assessment of mutant p53 content with the assay permits measurement of the wild-type p53 transduction efficiency into SF-188, U251MG and HUG31 glioblastoma cells. One reverse transcription primer tracks the wild-type/mutant ratio of endogenous p53 mRNA (P2), and the other the wild-type/mutant ratio of both endogenous and exogenous p53 mRNA (P1). Following infection of cell lines homozygous for mutant p53, the apparent transduction efficiency calculated (τ(o) = [P1 - P2]/[1 + P2]) correlated with the level of p21 expression. Transduction efficiency in heterozygous wild-type/mutant HUG31 cells increased linearly with multiplicity of infection (MOI) for τ(o) value, in keeping with theoretical predictions. These results suggest that the yeast p53 functional assay may be a useful tool for monitoring p53 gene therapy.

AB - Monitoring the transduction efficiency is of paramount importance in gene therapy. To monitor adenovirus-mediated wild-type p53 gene transfer, we have used a quantitative assay which tests the ability of human p53 to activate transcription in yeast. Selective amplification of cellular and viral p53 transcripts followed by quantitative assessment of mutant p53 content with the assay permits measurement of the wild-type p53 transduction efficiency into SF-188, U251MG and HUG31 glioblastoma cells. One reverse transcription primer tracks the wild-type/mutant ratio of endogenous p53 mRNA (P2), and the other the wild-type/mutant ratio of both endogenous and exogenous p53 mRNA (P1). Following infection of cell lines homozygous for mutant p53, the apparent transduction efficiency calculated (τ(o) = [P1 - P2]/[1 + P2]) correlated with the level of p21 expression. Transduction efficiency in heterozygous wild-type/mutant HUG31 cells increased linearly with multiplicity of infection (MOI) for τ(o) value, in keeping with theoretical predictions. These results suggest that the yeast p53 functional assay may be a useful tool for monitoring p53 gene therapy.

KW - Adenovirus

KW - p53

KW - Transcripts

KW - Transduction efficiency

KW - Yeast p53 functional assay

UR - http://www.scopus.com/inward/record.url?scp=0031933020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031933020&partnerID=8YFLogxK

M3 - Article

C2 - 9614553

AN - SCOPUS:0031933020

VL - 5

SP - 339

EP - 344

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -